Azmi Nasser

955 total citations
36 papers, 731 citations indexed

About

Azmi Nasser is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Cognitive Neuroscience. According to data from OpenAlex, Azmi Nasser has authored 36 papers receiving a total of 731 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Psychiatry and Mental health, 11 papers in Pediatrics, Perinatology and Child Health and 11 papers in Cognitive Neuroscience. Recurrent topics in Azmi Nasser's work include Attention Deficit Hyperactivity Disorder (25 papers), Bipolar Disorder and Treatment (10 papers) and Pharmaceutical studies and practices (8 papers). Azmi Nasser is often cited by papers focused on Attention Deficit Hyperactivity Disorder (25 papers), Bipolar Disorder and Treatment (10 papers) and Pharmaceutical studies and practices (8 papers). Azmi Nasser collaborates with scholars based in United States, United Kingdom and Czechia. Azmi Nasser's co-authors include Christian Heidbreder, Paul J. Fudala, Roberto Goméni, Stefan Schwabe, Joseph T. Hull, Tesfaye Liranso, Gregory D. Busse, Robert L. Findling, Bo Zheng and Andrew J. Cutler and has published in prestigious journals such as Neurology, Journal of the American Academy of Child & Adolescent Psychiatry and Clinical Pharmacokinetics.

In The Last Decade

Azmi Nasser

36 papers receiving 661 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Azmi Nasser United States	18	502	213	136	135	92	36	731
Stefan Unterecker Germany	14	372 0.7×	97 0.5×	235 1.7×	52 0.4×	116 1.3×	71	818
Jeffrey G. Stark United States	13	243 0.5×	77 0.4×	44 0.3×	40 0.3×	69 0.8×	29	470
Mark Montebello Australia	10	114 0.2×	64 0.3×	386 2.8×	86 0.6×	73 0.8×	34	574
Gail Somer Canada	12	82 0.2×	66 0.3×	123 0.9×	135 1.0×	54 0.6×	19	658
Michele C. Meyer United States	8	231 0.5×	53 0.2×	51 0.4×	56 0.4×	76 0.8×	13	516
Anne Roussin France	16	58 0.1×	61 0.3×	99 0.7×	146 1.1×	61 0.7×	42	696
Rama Melkote United States	9	206 0.4×	46 0.2×	384 2.8×	30 0.2×	44 0.5×	16	662
Rebecca Casari Italy	11	124 0.2×	97 0.5×	76 0.6×	44 0.3×	20 0.2×	28	373
A.M. Burakov Russia	12	107 0.2×	78 0.4×	240 1.8×	259 1.9×	66 0.7×	21	845
D Ladewig Switzerland	17	128 0.3×	118 0.6×	196 1.4×	281 2.1×	114 1.2×	73	915

Countries citing papers authored by Azmi Nasser

Since Specialization

Citations

This map shows the geographic impact of Azmi Nasser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Azmi Nasser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Azmi Nasser more than expected).

Fields of papers citing papers by Azmi Nasser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Azmi Nasser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Azmi Nasser. The network helps show where Azmi Nasser may publish in the future.

Co-authorship network of co-authors of Azmi Nasser

This figure shows the co-authorship network connecting the top 25 collaborators of Azmi Nasser. A scholar is included among the top collaborators of Azmi Nasser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Azmi Nasser. Azmi Nasser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nasser, Azmi, Roberto Goméni, Gianpiera Ceresoli‐Borroni, et al.. (2024). Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease. Journal of Pharmacokinetics and Pharmacodynamics. 51(4). 385–393. 1 indexed citations

Wang, Zhao, et al.. (2024). Impact of Viloxazine Extended-Release Capsules (Qelbree®) on Select Cytochrome P450 Enzyme Activity and Evaluation of CYP2D6 Genetic Polymorphisms on Viloxazine Pharmacokinetics. Clinical Drug Investigation. 44(5). 303–317. 1 indexed citations

Nasser, Azmi, Joseph T. Hull, Jennifer Koch, et al.. (2023). Effects of Viloxazine ER (Qelbree®) on Weight and Height Trajectories: Interim Results From a Long-term, Open-Label Extension Trial in Pediatric ADHD. CNS Spectrums. 28(2). 218–218. 1 indexed citations

Nasser, Azmi, et al.. (2023). Evaluating the Impact of Caffeine on the Incidence of Adverse Events During Treatment with Viloxazine Extended-Release (Qelbree®) in Adults with ADHD. CNS Spectrums. 28(2). 234–235. 1 indexed citations

Faraone, Stephen V., Roberto Goméni, Joseph T. Hull, et al.. (2023). Response of peer relations and social activities to treatment with viloxazine extended‐release capsules (Qelbree ^® ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention‐deficit/hyperactivity disorder. Brain and Behavior. 13(4). e2910–e2910. 5 indexed citations

Nasser, Azmi, Joseph T. Hull, Tesfaye Liranso, et al.. (2022). A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. CNS Drugs. 36(8). 897–915. 32 indexed citations

Faraone, Stephen V., Roberto Goméni, Joseph T. Hull, et al.. (2022). Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial. Psychiatry Research. 318. 114922–114922. 13 indexed citations

Nasser, Azmi, Alisa R. Kosheleff, Joseph T. Hull, et al.. (2021). Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. 31(3). 214–226. 12 indexed citations

Faraone, Stephen V., Roberto Goméni, Joseph T. Hull, et al.. (2021). Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials. Psychiatry Research. 296. 113664–113664. 23 indexed citations

10.

Faraone, Stephen V., Roberto Goméni, Joseph T. Hull, et al.. (2021). Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials. Pediatric Drugs. 23(6). 583–589. 12 indexed citations

11.

Findling, Robert L., Azmi Nasser, Stefan Schwabe, et al.. (2021). Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. CNS Drugs. 35(6). 643–653. 40 indexed citations

12.

Nasser, Azmi, Tesfaye Liranso, Joseph T. Hull, et al.. (2021). Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial. Clinical Therapeutics. 43(4). 684–700. 39 indexed citations

13.

Wang, Zhao, et al.. (2021). Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (QelbreeTM) in Healthy Adult Subjects. European Journal of Drug Metabolism and Pharmacokinetics. 47(1). 69–79. 6 indexed citations

14.

Goméni, Roberto, et al.. (2020). <p>Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR®) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation</p>. Clinical Pharmacology Advances and Applications. Volume 12. 135–147. 1 indexed citations

15.

Schwabe, Stefan, et al.. (2020). Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults. Clinical Drug Investigation. 41(2). 149–159. 19 indexed citations

16.

Nasser, Azmi, Mark K. Greenwald, Bradley Vince, et al.. (2015). Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder. Journal of Clinical Psychopharmacology. 36(1). 18–26. 53 indexed citations

17.

Nasser, Azmi, Christian Heidbreder, Yongzhen Liu, & Paul J. Fudala. (2015). Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers. Clinical Pharmacokinetics. 54(8). 837–849. 29 indexed citations

18.

Nasser, Azmi, Paul J. Fudala, Bo Zheng, Yongzhen Liu, & Christian Heidbreder. (2014). A Randomized, Double-Blind, Placebo-Controlled Trial of RBP-8000 in Cocaine Abusers: Pharmacokinetic Profile of RBP-8000 and Cocaine and Effects of RBP-8000 on Cocaine-Induced Physiological Effects. Journal of Addictive Diseases. 33(4). 289–302. 23 indexed citations

19.

Laffont, Céline M., Roberto Goméni, Bo Zheng, et al.. (2014). Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP‐7000, a New Sustained‐Release Formulation of Risperidone, in Schizophrenia Patients on Stable Oral Risperidone Treatment. Clinical Pharmacokinetics. 53(6). 533–543. 27 indexed citations

20.

Goméni, Roberto, Christian Heidbreder, Paul J. Fudala, & Azmi Nasser. (2013). A model‐based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP‐7000, a new, long‐acting, sustained‐released formulation of risperidone. The Journal of Clinical Pharmacology. 53(10). 1010–1019. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact